Assessing the efficacy and safety in novel drug candidates for Alzheimer's disease utilizes a rigorous evaluation process. Preclinical studies often involve in vitro and in vivo models to assess the potential effectiveness in targeting disease-related pathways. Once promising candidates emerge, they enter clinical trials that are conducted with hu